bioRxiv Science⌕ Search

Biology subjects

Appleton, B. D.

Publications and source records attributed to Appleton, B. D..

2 recordsLinked to original sources

Oxidized phospholipid oxPAPC induces a Th1-like phenotype in regulatory T cells and inhibits their protective function in atherosclerosis

BackgroundRegulatory T cells (Tregs) are protective in atherosclerosis but reduced during disease progression due to cell death and loss of stability. However, the mechanisms of Treg dysfunction remain unknown. Oxidized phospholipids (oxPLs) are abundant in atherosclerosis and can activate innate immune cells, but there is limited information regarding their impact on T cells. Given Treg loss during atherosclerosis progression and oxPL levels in the plaque microenvironment, we sought to determine whether oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC), an oxPL associated with atherosclerotic plaques, alters Treg differentiation and function. MethodsNaive CD4+ T cells were cultured under Treg, Th1, and Th17 polarizing conditions with or without oxPAPC and assessed by flow cytometry. Gene expression in oxPAPC-treated Tregs was analyzed by bulk RNA sequencing. Functional studies of oxPAPC-induced Tregs were performed by co-culturing Tregs with CTV-labeled CD8+ cells in vitro. In vivo suppression of atherosclerosis was evaluated by adoptively transferring control or oxPAPC-treated Tregs to hyperlipidemic Ldlr-/- mice. ResultsCompared to controls, oxPAPC-treated Tregs were less viable but expressed higher levels of the Th1-associated markers T-bet, CXCR3, and IFN-{gamma}. Th1 and Th17 skewing cultures were unaltered by oxPAPC. IFN-{gamma} is linked to Treg instability, thus Treg polarization experiments were repeated using Ifngr1-/- CD4+ T cells. IFN{gamma}R1 deficiency did not improve cell viability in oxPAPC-treated Tregs, however, T-bet and IFN-{gamma} expression was not increased suggesting a role for IFN-{gamma} signaling. OxPAPC-treated Tregs were less suppressive in vitro, and adoptive transfer studies in hyperlipidemic Ldlr-/- mice showed that oxPAPC-induced Tregs possessed altered tissue homing and were insufficient to inhibit atherosclerosis progression. ConclusionsOxPAPC elicits Treg-specific changes that induce a Th1-like phenotype dependent on IFN-{gamma} signaling. This is biologically relevant as oxPAPC-treated Tregs are unable to reduce atherosclerosis progression in Ldlr-/- mice. This study supports a role for oxPLs in negatively impacting Treg differentiation and atheroprotective function.

immunology↗

Inhibition of miR-22-3p reduces kidney disease associated with systemic lupus erythematosus

Cellular microRNAs (miRNA) have proven to be critical regulators of inflammatory gene expression across many pathways within autoimmunity. Circulating miRNAs serve as a new class of disease biomarkers. Nevertheless, the functional roles of miRNAs, particularly extracellular miRNAs, in systemic lupus erythematosus (SLE) remain poorly understood. Therefore, we aimed to link changes in extracellular miRNAs to lymphocyte gene regulation and the pathophysiology of SLE. Here, we demonstrate that circulating miR-22-3p levels are associated with SLE, and miR-22-3p regulates T and B cell function and SLE-associated kidney disease. Based on high-throughput small RNA sequencing and real-time PCR, extracellular miR-22-3p levels were found to be significantly increased in whole plasma in human SLE subjects. To determine the functional impact of miR-22-3p in SLE, miR-22-3p loss-of-function studies were performed in a mouse model of SLE (B6.SLE1.2.3). We found that in vivo administration of locked-nucleic acid inhibitors of miR-22-3p (LNA-22) reduced lymphocyte accumulation in both the spleen and lymph nodes compared to LNA scramble (LNA-Scr) control-treated mice. Strikingly, LNA-22-3p treatments reduced kidney disease pathology and glomerular IgG deposition compared to LNA-Scr treatments in SLE mice. Moreover, miR-22-3p inhibition reduced the proportion of T effector memory IFN-{gamma} producing CD4+ T cells, suggesting that miR-22-3p regulates Th1 T cell differentiation. We also found that miR-22 inhibition in mice reduced STAT1 phosphorylation in the kidney which was correlated with loss of IFN-{gamma} production by splenic CD4+ T cells. In conclusion, our findings suggest that miR-22-3p is a critical regulator of SLE-associated CD4+ T cell immunity and kidney disease. These results provide therapeutic potential for limiting splenic Th1 signaling and preventing the progression of lupus nephritis.\n\nKey FindingsO_LIExtracellular miR-22-3p levels are significantly increased in plasma from human SLE subjects.\nC_LIO_LIInhibition of miR-22-3p in vivo significantly reduced lymphocyte accumulation in both the spleen and lymph nodes in a mouse model of SLE, thus reducing splenomegaly and lymphadenopathy.\nC_LIO_LImiR-22-3p inhibition significantly reduced IFN-{gamma} expression and secretion from splenic T cell subsets.\nC_LIO_LIInhibition of miR-22-3p in vivo resulted in decreased IgG deposition in the kidney, decreased STAT1 phosphorylation, and decreased kidney disease in a mouse model of SLE.\nC_LI

immunology↗